---
document_datetime: 2025-12-02 05:09:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/plavix.html
document_name: plavix.html
version: success
processing_time: 0.1356702
conversion_datetime: 2025-12-29 22:49:03.094642
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Plavix

[RSS](/en/individual-human-medicine.xml/65510)

##### Authorised

This medicine is authorised for use in the European Union

clopidogrel Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Plavix](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77959)
- [More information on Plavix](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Plavix is a medicine used to prevent problems caused by blood clots in adults who have:

- recently had a myocardial infarction (heart attack). Plavix can be started between a few days and 35 days after the attack;
- recently had an ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). Plavix can be started between seven days and six months after the stroke;
- peripheral arterial disease (problems with blood flow in the arteries);
- a condition known as 'acute coronary syndrome', when it should be given with acetylsalicylic acid (also known as aspirin). Acute coronary syndrome is a group of heart problems that includes heart attacks and unstable angina (a severe type of chest pain). Some of these patients may be undergoing percutaneous coronary intervention (a procedure that unblocks blood vessels of the heart to restore its blood supply) and may have had a stent inserted (a short tube placed in an artery to prevent it closing up). Others may benefit from thrombolytic or fibrinolytic treatment (treatments to dissolve blood clots).
- atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with acetylsalicylic acid. It is used in those patients who have at least one risk factor for vascular events such as a heart attack or stroke, cannot take vitamin K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.

Plavix contains the active substance clopidogrel.

Expand section

Collapse section

## How is Plavix used?

Plavix is available as tablets and can only be obtained with a prescription.

Plavix is taken once a day as a 75 mg tablet. Use of a loading dose (an initial higher dose) and the duration of treatment depend on the age of the patient and the disease being treated. For patients undergoing a percutaneous coronary intervention or eligible for thrombolytic or fibrinolytic therapy, treatment should start as early as possible after start of symptoms.

For more information about using Plavix, see the package leaflet or contact your doctor or pharmacist.

## How does Plavix work?

The active substance in Plavix, clopidogrel, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. Blood clots are caused by cells in the blood called platelets sticking together. Clopidogrel stops the platelets sticking together by blocking a substance called ADP from attaching to a receptor on their surface. This stops the platelets becoming 'sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.

## What benefits of Plavix have been shown in studies?

Plavix was more effective than acetylsalicylic acid at preventing new ischaemic events. In a study in around 19,000 patients who had recently had a heart attack or an ischaemic stroke, or who had established peripheral artery disease, 939 patients who were given Plavix experienced a new ischemic event (heart attack, ischaemic stroke or death) over a period of one to three years, compared with 1,020 patients who were given acetylsalicylic acid. This corresponds to a relative reduction in risk of 9% compared with acetylsalicylic acid and means that fewer patients will have new ischaemic events if they receive Plavix than if they receive acetylsalicylic acid.

In three studies involving over 61,000 patients with non?ST segment elevation acute coronary syndrome, 2,172 of whom had a stent inserted during the study, Plavix was given in combination with acetylsalicylic acid and compared with placebo (a dummy treatment). In these studies, which differed in duration from up to 8 days to up to one year, the overall relative risk of an event such as a blocked artery, another heart attack or death was reduced by 20% when patients were given Plavix and acetylsalicylic acid compared with placebo. There was also a reduction in the patients who had a stent inserted. In 2 studies in 49,000 patients with ST segment elevation myocardial infarction, fewer patients on Plavix had events than patients on placebo (262 against 377 in the CLARITY study, and 2,121 against 2,310 in the COMMIT study).

In a study in around 7,500 patients with atrial fibrillation who had at least one risk factor for vascular events and who could not take vitamin K antagonist therapy, patients were given Plavix together with acetylsalicylic acid or placebo for an average of three years. In this study, Plavix plus acetylsalicylic acid reduced the risk of new events by 11% compared with placebo taken with acetylsalicylic acid, with the largest reduction (28%) seen for stroke.

Study results published in medical journals showed that Plavix was effective for up to 12 months at reducing the occurrence of heart attack, stroke or death in patients treated for heart attack with ST-segment elevation who are having a percutaneous coronary intervention.

## What are the risks associated with Plavix?

Bleeding reactions are the most common side effects reported with Plavix. The most common of these (which may affect up to 1 in 10 people) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), bruising and bleeding where the skin is punctured.

Other side effects (which may affect up to 1 in 10 people) are diarrhoea, abdominal pain (stomach ache) and dyspepsia (heartburn).

For the full list of side effects of Plavix, see the package leaflet.

Plavix must not be used in people who may be hypersensitive (allergic) to clopidogrel or any of the other ingredients. It must not be used in patients who have severe liver disease or a disease that may cause bleeding such as a stomach ulcer or bleeding in the brain.

## Why is Plavix authorised in the EU?

The European Medicines Agency decided that Plavix's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Plavix?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Plavix have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Plavix are continuously monitored. Suspected side effects reported with Plavix are carefully evaluated and any necessary action taken to protect patients.

## Other information about Plavix

Plavix received a marketing authorisation valid throughout the EU on 14 July 1998.

Plavix : EPAR - Medicine Overview

English (EN) (117.29 KB - PDF)

**First published:** 13/10/2009

**Last updated:** 15/02/2023

[View](/en/documents/overview/plavix-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-473)

български (BG) (129.59 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/bg/documents/overview/plavix-epar-medicine-overview_bg.pdf)

español (ES) (117.02 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/es/documents/overview/plavix-epar-medicine-overview_es.pdf)

čeština (CS) (123.89 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/cs/documents/overview/plavix-epar-medicine-overview_cs.pdf)

dansk (DA) (114.99 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/da/documents/overview/plavix-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.69 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/de/documents/overview/plavix-epar-medicine-overview_de.pdf)

eesti keel (ET) (115.01 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/et/documents/overview/plavix-epar-medicine-overview_et.pdf)

ελληνικά (EL) (130.82 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/el/documents/overview/plavix-epar-medicine-overview_el.pdf)

français (FR) (121 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/fr/documents/overview/plavix-epar-medicine-overview_fr.pdf)

hrvatski (HR) (119.02 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/hr/documents/overview/plavix-epar-medicine-overview_hr.pdf)

italiano (IT) (117.71 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/it/documents/overview/plavix-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (129.73 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/lv/documents/overview/plavix-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (120.16 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/lt/documents/overview/plavix-epar-medicine-overview_lt.pdf)

magyar (HU) (120.42 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/hu/documents/overview/plavix-epar-medicine-overview_hu.pdf)

Malti (MT) (123.93 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/mt/documents/overview/plavix-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.69 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/nl/documents/overview/plavix-epar-medicine-overview_nl.pdf)

polski (PL) (116.86 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/pl/documents/overview/plavix-epar-medicine-overview_pl.pdf)

português (PT) (113.24 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/pt/documents/overview/plavix-epar-medicine-overview_pt.pdf)

română (RO) (115.21 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/ro/documents/overview/plavix-epar-medicine-overview_ro.pdf)

slovenčina (SK) (117.38 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/sk/documents/overview/plavix-epar-medicine-overview_sk.pdf)

slovenščina (SL) (113.95 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/sl/documents/overview/plavix-epar-medicine-overview_sl.pdf)

Suomi (FI) (110.56 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/fi/documents/overview/plavix-epar-medicine-overview_fi.pdf)

svenska (SV) (115.11 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

15/02/2023

[View](/sv/documents/overview/plavix-epar-medicine-overview_sv.pdf)

Plavix : EPAR - Risk management plan

English (EN) (1.31 MB - PDF)

**First published:** 12/02/2021

**Last updated:** 16/04/2025

[View](/en/documents/rmp/plavix-epar-risk-management-plan_en.pdf)

## Product information

Plavix : EPAR - Product Information

English (EN) (416.7 KB - PDF)

**First published:** 13/10/2009

**Last updated:** 14/07/2025

[View](/en/documents/product-information/plavix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-875)

български (BG) (693.04 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/bg/documents/product-information/plavix-epar-product-information_bg.pdf)

español (ES) (461.59 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/es/documents/product-information/plavix-epar-product-information_es.pdf)

čeština (CS) (457.54 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/cs/documents/product-information/plavix-epar-product-information_cs.pdf)

dansk (DA) (386.49 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/da/documents/product-information/plavix-epar-product-information_da.pdf)

Deutsch (DE) (397.68 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/de/documents/product-information/plavix-epar-product-information_de.pdf)

eesti keel (ET) (345.8 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/et/documents/product-information/plavix-epar-product-information_et.pdf)

ελληνικά (EL) (564.38 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/el/documents/product-information/plavix-epar-product-information_el.pdf)

français (FR) (568.26 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/fr/documents/product-information/plavix-epar-product-information_fr.pdf)

hrvatski (HR) (425.37 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/hr/documents/product-information/plavix-epar-product-information_hr.pdf)

íslenska (IS) (410.13 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/is/documents/product-information/plavix-epar-product-information_is.pdf)

italiano (IT) (384.07 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/it/documents/product-information/plavix-epar-product-information_it.pdf)

latviešu valoda (LV) (458.37 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/lv/documents/product-information/plavix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (467.79 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/lt/documents/product-information/plavix-epar-product-information_lt.pdf)

magyar (HU) (742.37 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/hu/documents/product-information/plavix-epar-product-information_hu.pdf)

Malti (MT) (651.13 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/mt/documents/product-information/plavix-epar-product-information_mt.pdf)

Nederlands (NL) (526.55 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/nl/documents/product-information/plavix-epar-product-information_nl.pdf)

norsk (NO) (527.01 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/no/documents/product-information/plavix-epar-product-information_no.pdf)

polski (PL) (500.6 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/pl/documents/product-information/plavix-epar-product-information_pl.pdf)

português (PT) (532.8 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/pt/documents/product-information/plavix-epar-product-information_pt.pdf)

română (RO) (505.84 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/ro/documents/product-information/plavix-epar-product-information_ro.pdf)

slovenčina (SK) (446.94 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/sk/documents/product-information/plavix-epar-product-information_sk.pdf)

slovenščina (SL) (437.61 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/sl/documents/product-information/plavix-epar-product-information_sl.pdf)

Suomi (FI) (333.88 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/fi/documents/product-information/plavix-epar-product-information_fi.pdf)

svenska (SV) (544.99 KB - PDF)

**First published:**

13/10/2009

**Last updated:**

14/07/2025

[View](/sv/documents/product-information/plavix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000285292 11/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Plavix : EPAR - All Authorised presentations

English (EN) (50.38 KB - PDF)

**First published:** 05/11/2008

**Last updated:** 05/12/2018

[View](/en/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-199)

български (BG) (83.35 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/bg/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_bg.pdf)

español (ES) (87.15 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/es/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (81.55 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/cs/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (39.55 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/da/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.98 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/de/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (51.33 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/et/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (82.21 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/el/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_el.pdf)

français (FR) (66.31 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/fr/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (51.68 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/hr/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (111.44 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/is/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_is.pdf)

italiano (IT) (31.11 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/it/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (93.31 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/lv/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (69.68 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/lt/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (80.35 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/hu/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (75.16 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/mt/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (35.38 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/nl/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (66.79 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/no/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_no.pdf)

polski (PL) (89.31 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/pl/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_pl.pdf)

português (PT) (92.5 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/pt/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.32 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/ro/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (75.18 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/sk/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (74.17 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/sl/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (68.54 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/fi/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (39.11 KB - PDF)

**First published:**

05/11/2008

**Last updated:**

05/12/2018

[View](/sv/documents/all-authorised-presentations/plavix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Plavix Active substance clopidogrel hydrogen sulfate International non-proprietary name (INN) or common name clopidogrel Therapeutic area (MeSH)

- Stroke
- Peripheral Vascular Diseases
- Atrial Fibrillation
- Myocardial Infarction
- Acute Coronary Syndrome

Anatomical therapeutic chemical (ATC) code B01AC04

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

**Secondary prevention of atherothrombotic events**

Clopidogrel is indicated in:

- adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;
- adult patients suffering from acute coronary syndrome:
    - non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);
    - ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.
    - In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)

**Prevention of atherothrombotic and thromboembolic events in atrial fibrillation**

In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

## Authorisation details

EMA product number EMEA/H/C/000174 Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail

Opinion adopted 25/03/1998 Marketing authorisation issued 15/07/1998 Revision 53

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Plavix : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (229.24 KB - PDF)

**First published:** 14/07/2025

[View](/en/documents/procedural-steps-after/plavix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Plavix : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (411.18 KB - PDF)

**First published:** 13/10/2009

**Last updated:** 14/07/2025

[View](/en/documents/procedural-steps-after/plavix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Plavix-H-C-xxxx-WS-2150 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/55817/2023

English (EN) (1.66 MB - PDF)

**First published:** 15/02/2023

[View](/en/documents/variation-report/plavix-h-c-xxxx-ws-2150-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Plavix (WS-2150)

Adopted

Reference Number: EMA/862231/2022

English (EN) (127.69 KB - PDF)

**First published:** 11/11/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-plavix-ws-2150_en.pdf)

Plavix-H-C-174-WS-1769 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/657331/2020

English (EN) (2.64 MB - PDF)

**First published:** 12/02/2021

[View](/en/documents/variation-report/plavix-h-c-174-ws-1769-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Plavix (WS-1769)

Adopted

Reference Number: EMA/CHMP/668777/2020

English (EN) (152.86 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-plavix-ws-1769_en.pdf)

Plavix-H-C-174-II-0091 : EPAR - Assessment Report - Variation

Adopted

English (EN) (461.39 KB - PDF)

**First published:** 01/04/2011

**Last updated:** 01/04/2011

[View](/en/documents/variation-report/plavix-h-c-174-ii-0091-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Plavix

Adopted

Reference Number: EMA/CHMP/740480/2010

English (EN) (130.18 KB - PDF)

**First published:** 19/11/2010

**Last updated:** 19/11/2010

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-plavix_en.pdf)

Plavix-H-C-174-II-0061 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (604.87 KB - PDF)

**First published:** 13/07/2007

**Last updated:** 13/07/2007

[View](/en/documents/scientific-discussion-variation/plavix-h-c-174-ii-0061-epar-scientific-discussion-variation_en.pdf)

Plavix : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (102.24 KB - PDF)

**First published:** 24/10/2006

**Last updated:** 24/10/2006

[View](/en/documents/steps-after-cutoff/plavix-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

Plavix-H-C-174-II-0051 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (1.18 MB - PDF)

**First published:** 24/10/2006

**Last updated:** 24/10/2006

[View](/en/documents/scientific-discussion-variation/plavix-h-c-174-ii-0051-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Plavix : EPAR - Scientific Discussion

English (EN) (300.22 KB - PDF)

**First published:** 24/10/2006

**Last updated:** 24/10/2006

[View](/en/documents/scientific-discussion/plavix-epar-scientific-discussion_en.pdf)

Plavix : EPAR - Procedural steps taken before authorisation

English (EN) (91 KB - PDF)

**First published:** 24/10/2006

**Last updated:** 24/10/2006

[View](/en/documents/procedural-steps/plavix-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Plavix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022) 11/11/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Plavix : EPAR - Product information - tracked changes

English (EN) (174.23 KB - DOCX)

**First published:** 14/07/2025

[View](/en/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-74)

български (BG) (603.5 KB - DOC)

**First published:**

14/07/2025

[View](/bg/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_bg.doc)

español (ES) (463.5 KB - DOC)

**First published:**

14/07/2025

[View](/es/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_es.doc)

čeština (CS) (523 KB - DOC)

**First published:**

14/07/2025

[View](/cs/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (444 KB - DOC)

**First published:**

14/07/2025

[View](/da/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_da.doc)

Deutsch (DE) (485.5 KB - DOC)

**First published:**

14/07/2025

[View](/de/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_de.doc)

eesti keel (ET) (384 KB - DOC)

**First published:**

14/07/2025

[View](/et/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_et.doc)

ελληνικά (EL) (602 KB - DOC)

**First published:**

14/07/2025

[View](/el/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_el.doc)

français (FR) (209.43 KB - DOCX)

**First published:**

14/07/2025

[View](/fr/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (635 KB - DOC)

**First published:**

14/07/2025

[View](/hr/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_hr.doc)

íslenska (IS) (420.5 KB - DOC)

**First published:**

14/07/2025

[View](/is/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_is.doc)

italiano (IT) (428 KB - DOC)

**First published:**

14/07/2025

[View](/it/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (529 KB - DOC)

**First published:**

14/07/2025

[View](/lv/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_lv.doc)

lietuvių kalba (LT) (488.5 KB - DOC)

**First published:**

14/07/2025

[View](/lt/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_lt.doc)

magyar (HU) (599.5 KB - DOC)

**First published:**

14/07/2025

[View](/hu/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (189.45 KB - DOCX)

**First published:**

14/07/2025

[View](/mt/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (137.66 KB - DOCX)

**First published:**

14/07/2025

[View](/nl/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (149.89 KB - DOCX)

**First published:**

14/07/2025

[View](/no/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_no.docx)

polski (PL) (483 KB - DOC)

**First published:**

14/07/2025

[View](/pl/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_pl.doc)

português (PT) (139.46 KB - DOCX)

**First published:**

14/07/2025

[View](/pt/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_pt.docx)

română (RO) (595 KB - DOC)

**First published:**

14/07/2025

[View](/ro/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_ro.doc)

slovenčina (SK) (539 KB - DOC)

**First published:**

14/07/2025

[View](/sk/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (560.5 KB - DOC)

**First published:**

14/07/2025

[View](/sl/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_sl.doc)

Suomi (FI) (436.5 KB - DOC)

**First published:**

14/07/2025

[View](/fi/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_fi.doc)

svenska (SV) (155.22 KB - DOCX)

**First published:**

14/07/2025

[View](/sv/documents/product-information-tracked-changes/plavix-epar-product-information-tracked-changes_sv.docx)

#### More information on Plavix

- [EMEA-000049-PIP01-07-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000049-pip01-07-m03)
- [Treatment patterns in acute myocardial infarction patients initiated with prasugrel or clopidogrel during the index hospitalisation with one year follow-up (H7T-FR-B016) - post-authorisation study](https://catalogues.ema.europa.eu/study/20451)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 14/07/2025

## Share this page

[Back to top](#main-content)